Journal of Nanobiotechnology (Mar 2022)

A drug-free nanozyme for mitigating oxidative stress and inflammatory bowel disease

  • Feng Zeng,
  • Yahong Shi,
  • Chunni Wu,
  • Jianming Liang,
  • Qixin Zhong,
  • Karen Briley,
  • Bin Xu,
  • Yongzhuo Huang,
  • Manmei Long,
  • Cong Wang,
  • Jian Chen,
  • Yonghua Tang,
  • Xinying Li,
  • Mengda Jiang,
  • Luting Wang,
  • Qin Xu,
  • Liu Yang,
  • Peng Chen,
  • Shengzhong Duan,
  • Jingyuan Xie,
  • Cong Li,
  • Yingwei Wu

DOI
https://doi.org/10.1186/s12951-022-01319-7
Journal volume & issue
Vol. 20, no. 1
pp. 1 – 17

Abstract

Read online

Abstract Inflammatory bowel disease (IBD) is an incurable disease of the gastrointestinal tract with a lack of effective therapeutic strategies. The proinflammatory microenvironment plays a significant role in both amplifying and sustaining inflammation during IBD progression. Herein, biocompatible drug-free ceria nanoparticles (CeNP-PEG) with regenerable scavenging activities against multiple reactive oxygen species (ROS) were developed. CeNP-PEG exerted therapeutic effect in dextran sulfate sodium (DSS)-induced colitis murine model, evidenced by corrected the disease activity index, restrained colon length shortening, improved intestinal permeability and restored the colonic epithelium disruption. CeNP-PEG ameliorated the proinflammatory microenvironment by persistently scavenging ROS, down-regulating the levels of multiple proinflammatory cytokines, restraining the proinflammatory profile of macrophages and Th1/Th17 response. The underlying mechanism may involve restraining the co-activation of NF-κB and JAK2/STAT3 pathways. In summary, this work demonstrates an effective strategy for IBD treatment by ameliorating the self-perpetuating proinflammatory microenvironment, which offers a new avenue in the treatment of inflammation-related diseases. Graphical Abstract

Keywords